WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2001087039) TREATMENT OF NEOPLASIA / TRANSFORMATION USING PITUITARY TUMOR TRANSFORMING GENE 2
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2001/087039    International Application No.:    PCT/US2001/015255
Publication Date: 22.11.2001 International Filing Date: 12.05.2001
Chapter 2 Demand Filed:    12.12.2001    
IPC:
A61K 38/00 (2006.01), A61K 48/00 (2006.01), C07K 14/47 (2006.01), C07K 14/82 (2006.01)
Applicants: CEDARS-SINAI MEDICAL CENTER [US/US]; 8700 Beverly Boulevard Los Angeles, CA 90048-1869 (US)
Inventors: PREZANT, Toni, Rita; (US).
HEANEY, Anthony, P.; (US).
MELMED, Shlomo; (US)
Agent: STEINBERG, Nisan, A.; Sidley Austin Brown & Wood 555 W. Fifth Street Los Angeles, CA 90013-1010 (US)
Priority Data:
09/569,956 12.05.2000 US
09/687,911 13.10.2000 US
09/730,469 04.12.2000 US
09/777,422 05.02.2001 US
09/854,326 11.05.2001 US
Title (EN) TREATMENT OF NEOPLASIA / TRANSFORMATION USING PITUITARY TUMOR TRANSFORMING GENE 2
(FR) METHODE DE REGULATION DE L'ACTIVITE BIOLOGIQUE DU GENE DE TRANSFORMATION D'UNE TUMEUR DE L'HYPOPHYSE (PTTG)1 A L'AIDE DU PTTG2
Abstract: front page image
(EN)Disclosed is a method of inhibiting neoplastic cellular proliferation and/or transformation of mammalian breast or ovarian cells, including cells of human origin, in vitro or in vivo. The inventive method involves the use of a pituitary tumor transforming gene (PTTG)2 peptide, which has the ability to regulate endogenous $m(f)i$m(g)PTTG1$m(f)/i$m(g) expression and/or function in a dominant negative manner. In some embodiments, the invention is directed to gene-based treatments that deliver PTTG2-encoding polynucleotides to mammalian cells, whether in vitro or in vivo, to inhibit the endogenous expression of $m(f)i$m(g)PTTG1$m(f)/i$m(g). Other embodiments are directed to peptide-based treatments that deliver PTTG2 peptide molecules to the cells, which inhibit endogenous $m(f)i$m(g)PTTG1$m(f)/i$m(g) expression and/or $m(f)i$m(g)PTTG1$m(f)/i$m(g) function. Kits useful in practicing the inventive method are also disclosed.
(FR)L'invention concerne une méthode visant à inhiber la prolifération et/ou la transformation cellulaire néoplastique de cellules mammaliennes du sein ou des ovaires, y compris des cellules d'origine humaine, in vitro ou in vivo. La méthode de l'invention consiste à utiliser un peptide du gène de transformation d'une tumeur de l'hypophyse (PTTG)2, ayant la capacité de réguler l'expression et/ou la fonction endogène du $m(f)I$m(g)PTTG1$m(f)/I$m(g) de façon négative. Dans certains modes de réalisation, l'invention concerne des traitements à partir de gènes délivrant des polynucléotides codant pour le PTTG2 à des cellules mammaliennes, in vitro ou in vivo, afin d'inhiber l'expression endogène du $m(f)I$m(g)PTTG1$m(f)/I$m(g). D'autres modes de réalisation concernent des traitements à partir de peptides délivrant des molécules peptidiques du PTTG2 aux cellules, inhibant l'expression endogène du $m(f)I$m(g)PTTG1$m(f)/I$m(g) et/ou la fonction du $m(f)I$m(g)PTTG1$m(f)/I$m(g). L'invention concerne également des kits utilisés dans cette méthode.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)